E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Uunresectable or metastatic hepatocellular carcinoma |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10073071 |
E.1.2 | Term | Hepatocellular carcinoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety profile and tolerability of repeated administrations of milciclib in Child-Pugh "A" unresectable HCC patients who failed or are not eligible for Sorafenib or who actively refused it (presenting as naïve, progressing, recurrent or metastatic disease). |
|
E.2.2 | Secondary objectives of the trial |
• To document any antitumor activity of milciclib in patients with recurrent or metastatic unresectable HCC who have failed the standard therapy or who are not able to tolerate the standard therapy or who actively refused it. • To assess additional markers of tumor control to further characterize the efficacy profile of milciclib. • To evaluate the pharmacokinetic profile of milciclib and its metabolite in Child Pugh "A" HCC patients. Exploratory Objective: To evaluate the role of predictive and/or pharmacodynamic biomarkers of response to milciclib. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients with diagnosis of HCC, confirmed by histology or radiology according to AASLD/EASL criteria prior to the start of the investigational product. Imaging characteristics should be retrieved from at least a 3-phase liver protocol CT or MRI with target tumor lesion(s) demonstrating arterial hyper-enhancement and wash-out in the venous phase;
- Tumor stages eligible for the study are defined as: a. HCC within the Barcelona Clinic Liver Cancer (BCLC) stage C. In case of portal vein thrombosis (PVT) an associated target lesion in the liver parenchyma should be clearly defined. PVT without associated target lesion are not eligible to the study; b. Untreatable post-chemoembolization (TACE) or post-radioembolization (TARE) progression defined as BCLC stage B or C with radiographic progression according to mRECIST after TACE or TARE not eligible for further surgical or loco-regional therapy; c. Recurring HCC non eligible for pre-transplant downstaging protocols or for resection;
- Patients must have failed sorafenib treatment or be intolerant to sorafenib or actively refusing sorafenib a. Failing sorafenib treatment is defined if after ≥ 14 days of therapy (not necessarily consecutive) radiology progression is ascertained according to mRECIST; b. Intolerant to sorafenib treatment is defined as a sorafenib related Grade 2 or greater adverse event (CTC-AE) that continues or recurs after sorafenib treatment interruption for 7 days or dose reduction; c. Active refusal should be documented by a written and signed patient declaration to be filed in the clinical records;
- Child-Pugh score 6 (class A);
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Local or loco-regional therapy (i.e., surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radioembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed ≥4 weeks prior to study entry with documentation of progressive or recurrent disease;
|
|
E.4 | Principal exclusion criteria |
- Prior use of any systemic anti-cancer therapy (including experimental agents and immunotherapy) except for sorafenib and second line tretatment with regorafenib discontinued for intolerance within 14 days;
- Known fibrolamellar HCC or mixed hepato-cholangiocarcinoma;
- Grade 3 oesophageal varices, regardless of previous bleeding episodes on endoscopy perfomed no more than in the last 12 months;
- Clinical meaningful ascites defined as CTCAE Grade≥2. Patient who have been on a stable medication regimen for at least 2 months to manage ascites are eligible if they show no ascites at the clinical examination. Patients with clinically undetectable ascites who are Child A with detectable ascites at CT/MRI are eligible to the protocol;
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall safety profile, evaluated on the basis of laboratory (i.e. hematology and blood chemistry, urinalysis, vital signs, ophthalmologic examinations) and adverse events emerging during the trial will be determined. The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 will be used for the severity grading of vital signs, adverse events and of hematological and blood chemistry abnormalities. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From the signature of Informed Consent to 30 days after last dose intake. |
|
E.5.2 | Secondary end point(s) |
1. Objective Response Rate (ORR), i.e., confirmed CR + confirmed PR. The objective tumor assessment will be made according to the modified Response Evaluation Criteria In Solid Tumors (mRECIST) criteria for HCC. Conventional RECIST 1.1 will be also assessed. ORR will be assessed locally and confirmed by an Independent Central Review. 2. Progression-free survival (PFS) evaluated since study treatment start to progression, based on mRECIST tumor assessment, or death for any causes. 3. Time to progression (TTP) evaluated since study treatment start to progression, based on mRECIST tumor assessment or death due to disease progression in the absence of previous documented PD. 4. Proportion of evaluable patients known to be alive and progression free based on mRECIST tumor assessment at ≥3 months since study treatment start out of the total number of evaluable patients (TTP-3 months). 5. Duration of overall response (DoR), measured from the time measurement criteria are first met for CR/PR, based on mRECIST tumor assessment, until the first date that recurrence or PD is objectively documented or death date due to tumor progression in the absence of previous documented PD.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. At screening, during treatment at Day 45, at Day 90 and in the follow-up period at Day 180 for patients not progressed at previous assessment; 2, 3, 5) All study period; 4) After 3 months since treatment started;
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Greece |
Israel |
Italy |
Turkey |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit last subject including follow up |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |